Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Biotechnology company Biogen (BIIB) announced on Monday plans for new headquarters at Kendall Common, located at 75 Broadway ...

Biogen (BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year ...

Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty ...

SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s (NASDAQ:BIIB) recent buyout ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited takeover has now passed, and in the absence of clear ...

The company’s pipeline includes promising treatments for NASH and inflammatory bowel diseases. 7. Biogen Inc. Market Cap: $61.8 billion Key Focus: Neuroscience, rare genetic disorders Latest ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...